Clinical and biological parameters among patients achieving minimal disease activity and patients with an active disease after 6 months
| Minimal disease activity (n=24) | Active disease (n=11) | P value | |
| Age at disease onset (years), median (range) | 8.5 (1.1–15.8) | 12.6 (2.8–16.7) | ns |
| Disease duration (years), median (range) | 2.5 (0.2–15.1) | 3.3 (0.1–8.9) | ns |
| Female sex, n (%) | 12 (50.0) | 5 (45.5) | ns |
| Categories of JIA, n (%) | |||
| Systemic | 3 (12.5) | 1 (9.1) | ns |
| Oligoarthritis | 13 (54.2) | 4 (36.4) | |
| Persistent | 9 (37.5) | 3 (27.3) | |
| Extended | 4 (16.7) | 1 (9.1) | |
| PA-RF+ | 1 (4.2) | 1 (9.1) | |
| PA-RF− | 2 (8.3) | 1 (9.1) | |
| Psoriatic arthritis | 0 | 0 | |
| ERA | 5 (20.8) | 4 (36.4) | |
| Undifferentiated | 0 | 0 | |
| ANA+, n (%) | 7 (29.2) | 1 (9.1) | ns |
| Number of DMARDs used, mean (SEM) | 1.3 (0.2) | 2.1 (0.3) | ns |
| TJC, mean (SEM) | 1.7 (0.5) | 1.4 (0.5) | ns |
| SJC, mean (SEM) | 1.9 (0.6) | 3.1 (1.6) | ns |
| Physician VAS, mean (SEM) | 19.1 (3.8) | 27.8 (6.1) | ns |
| Patient/parent VAS, mean (SEM) | 18.9 (6.9) | 25.4 (8.2) | ns |
| CHAQ, mean (SEM) | 0.3 (0.1) | 0.4 (0.2) | ns |
| CRP (mg/L), mean (SEM) | 10.9 (3.5) | 11.5 (3.4) | ns |
| ESR (mm/hour), mean (SEM) | 21.5 (9.3) | 36.5 (8.7) | ns |
| DAS-28CRP, mean (SEM) | 2.5 (0.3) | 2.7 (0.4) | ns |
| JADAS10-CRP, mean (SEM) | 6.2 (1.3) | 8.6 (2.2) | ns |
| sCal (ng/mL), mean (SEM) | 12 138 (2133) | 5165 (1255) | * (0.03) |
Results are given as number±percentages, median±range or mean±SEM. Statistical significance (*p<0.05, ns: not significant) was assessed by Mann-Whitney test.
ANA, antinuclear antibody; CHAQ, Childhood Health Assessment Questionnaire; CRP, C-reactive protein; ERA, enthesitis-related arthritis; ESR, erythrocyte sedimentation rate; JIA, juvenile idiopathic arthritis; PA, polyarthritis; RF, rheumatoid factor; sCal, serum calprotectin; SJC, swollen joint count; TJC, tender joint count; VAS, disease evaluation on a Visual Analogue Scale.